Papers by Deepak L. Bhatt
Page 9 · newest first
- Clinical Profiles, Outcomes, and Sex Differences of Patients With STEMIJACC Asia · 2023
- Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trialsDiabetes Obesity and Metabolism · 2023
- Eicosapentaenoic acid (EPA) reduces pulmonary endothelial dysfunction and inflammation due to changes in protein expression during exposure to particulate matter air pollutionBiomedicine & Pharmacotherapy · 2023
- Correlation Between Periprocedural Myocardial Infarction, Mortality, and Quality of Life in Coronary Revascularization Trials: A Meta-analysisJournal of the Society for Cardiovascular Angiography & Interventions · 2023
- Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleedingEuropean Heart Journal · 2023
- Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular DiseaseJAMA Network Open · 2023
- Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors and Angiotensin Receptor–Neprilysin Inhibitors for Heart Failure in Black Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEuropean Journal of Heart Failure · 2023
- Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trialEuropean Heart Journal · 2023
- Mechanical Circulatory Support Devices in Acute Myocardial Infarction-Cardiogenic Shock: Current Studies and Future DirectionsJournal of the Society for Cardiovascular Angiography & Interventions · 2023
- Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With DiabetesJAMA Cardiology · 2023
- Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐ITJournal of the American Heart Association · 2023
- Assessment of Nonfatal Bleeding Events as a Surrogate for Mortality in Coronary Artery DiseaseJACC Advances · 2023
- Pulling Out All the Stops: A Case of Progressive DyspneaCirculation · 2023
- Predicting survival and neurological outcome in out-of-hospital cardiac arrest using machine learning: the SCARS modelEBioMedicine · 2023
- Combined Minimally Invasive Surgical and Percutaneous Catheter Ablation of Atrial FibrillationJournal of the American College of Cardiology · 2023
- Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programmeAnnals of the Rheumatic Diseases · 2023
- Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registryEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2023
- Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetesScientific Reports · 2023
- Utilization and Outcomes of Clinically Indicated Invasive Cardiac Care in Veterans with Acute Coronary Syndrome and Chronic Kidney DiseaseJournal of the American Society of Nephrology · 2023
- Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular diseaseDiabetes Obesity and Metabolism · 2023
- Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL SurveillanceTherapeutic Advances in Musculoskeletal Disease · 2023
- Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysisHeart International · 2023
- Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate ContinuesCurrent Atherosclerosis Reports · 2022
- Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialAnnals of the Rheumatic Diseases · 2022
- Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart FailureCirculation Heart Failure · 2022
- Efficacy of supermarket and web-based interventions for improving dietary quality: a randomized, controlled trialNature Medicine · 2022
- Health status and cognitive function for risk stratification in chronic coronary and peripheral artery diseaseEuropean Journal of Preventive Cardiology · 2022
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac EventsJAMA Network Open · 2022
- Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58Diabetes Care · 2022
- Palliative Care Utilization Among Hospitalized Patients With Common Chronic Conditions in the United StatesJournal of Palliative Care · 2022
- Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54European Heart Journal · 2022
- Hypertension management in patients with cardiovascular comorbiditiesEuropean Heart Journal · 2022
- Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionNew England Journal of Medicine · 2022
- Association of Post-Vaccination Adverse Reactions After Influenza Vaccine with Mortality and Cardiopulmonary Outcomes in Patients with High-Risk Cardiovascular Disease: The INVESTED TrialEuropean Journal of Heart Failure · 2022
- Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical TrialCirculation · 2022
- Serial troponin-T and long-term outcomes in suspected acute coronary syndromeEuropean Heart Journal · 2022
- Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statinsFrontiers in Cardiovascular Medicine · 2022
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
- Predicting radiocephalic arteriovenous fistula success with machine learningnpj Digital Medicine · 2022
- External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registryInternational Journal of Cardiology · 2022
- Trends in Blood Pressure Treatment Intensification in Older Adults With Hypertension in the United States, 2008 to 2018Hypertension · 2022
- Trends, predictors, and outcomes of transcatheter aortic valve implantation in patients with bicuspid aortic valve related disease: Insights from the Nationwide Inpatient Sample and Nationwide Readmission DatabaseCatheterization and Cardiovascular Interventions · 2022
- Case‐fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta‐analysisResearch and Practice in Thrombosis and Haemostasis · 2022
- Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trialEuropean Heart Journal · 2022
- Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trialEuropean Heart Journal · 2022
- Comparing direct oral anticoagulants versus vitamin K antagonist in patients with atrial fibrillation after transcatheter aortic valve replacement: an updated meta-analysisEuropean Heart Journal · 2022
- To compare efficacy and safety of direct oral anticoagulants in patients with concurrent atrial fibrillation and bioprosthetic heart valve repair or replacement: a systematic review and meta-analysisEuropean Heart Journal · 2022
- Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL SurveillanceAnnals of the Rheumatic Diseases · 2022
- Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)Clinical Cardiology · 2022
- Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United StatesSHILAP Revista de lepidopterología · 2022